Neuropilin 1 (NRP1) Human shRNA Lentiviral Particle (Locus ID 8829)

CAT#: TL311093V

NRP1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL311093A virus into HEK293 cells. TL311093A virus was prepared using lenti-shRNA TL311093A and TR30037 packaging kit.

Specifications

Product Data

• Locus ID: 8829
• Synonyms: BDCA4; CD304; NP1; NRP; VEGF165R
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: BC007533, NM_001024628, NM_001024629, NM_001244972, NM_001244973, NM_003873, NR_045259, NM_001330068, NM_001024629.1, NM_001024629.2, NM_001024628.1, NM_001024628.2, NM_003873.1, NM_003873.2, NM_003873.3, NM_003873.4, NM_003873.5, NM_001244973.1, NM_001244972.1, BC007533.1, BC007737, BC007737.2, NM_003873.7
• UniProt ID: O14786
• Summary: This gene encodes one of two neuropilins, which contain specific protein domains which allow them to participate in several different types of signaling pathways that control cell migration. Neuropilins contain a large N-terminal extracellular domain, made up of complement-binding, coagulation factor V/VIII, and meprin domains. These proteins also contains a short membrane-spanning domain and a small cytoplasmic domain. Neuropilins bind many ligands and various types of co-receptors; they affect cell survival, migration, and attraction. Some of the ligands and co-receptors bound by neuropilins are vascular endothelial growth factor (VEGF) and semaphorin family members. This protein has also been determined to act as a co-receptor for SARS-CoV-2 (which causes COVID-19) to infect host cells. [provided by RefSeq, Nov 2020]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).